Frequency Therapeutics Valuation
| KRRO Stock | 12.51 0.21 1.65% |
At this time, the firm appears to be undervalued. Frequency Therapeutics shows a prevailing Real Value of USD15.45 per share. The current price of the firm is USD12.51. Our model computes the value of Frequency Therapeutics from reviewing the firm fundamentals such as Shares Outstanding of 9.42 M, shares owned by insiders of 6.58 %, and Operating Margin of (17.65) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Frequency Therapeutics' valuation include:
Price Book 1.1953 | Enterprise Value | Enterprise Value Ebitda (5.60) | Price Sales 16.0596 | Enterprise Value Revenue 9.5732 |
Undervalued
Today
Please note that Frequency Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Frequency Therapeutics is based on 3 months time horizon. Increasing Frequency Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Frequency Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Frequency Stock. However, Frequency Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.51 | Real 15.45 | Target 19.33 | Hype 12.74 |
The intrinsic value of Frequency Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Frequency Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Frequency Therapeutics helps investors to forecast how Frequency stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Frequency Therapeutics more accurately as focusing exclusively on Frequency Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Frequency Therapeutics' intrinsic value based on its ongoing forecasts of Frequency Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Frequency Therapeutics' closest peers.
Frequency Therapeutics Cash |
|
Frequency Therapeutics Total Value Analysis
Frequency Therapeutics is now projected to have valuation of 70.56 M with market capitalization of 118.38 M, debt of 44.77 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Frequency Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
70.56 M | 118.38 M | 44.77 M |
Frequency Therapeutics Investor Information
About 93.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.2. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Frequency Therapeutics recorded a loss per share of 9.42. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 6th of November 2023. Based on the key indicators related to Frequency Therapeutics' liquidity, profitability, solvency, and operating efficiency, Frequency Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Frequency Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Frequency Therapeutics has an asset utilization ratio of 1.0 percent. This suggests that the Company is making USD0.01 for each dollar of assets. An increasing asset utilization means that Frequency Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Frequency Therapeutics Profitability Analysis
Based on Frequency Therapeutics' profitability indicators, Frequency Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Frequency Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-09-30 | Previous Quarter -25.8 M | Current Value -18.1 M | Quarterly Volatility 7.3 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.56 | 0.65 |
|
|
For Frequency Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Frequency Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Frequency Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Frequency Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Frequency Therapeutics over time as well as its relative position and ranking within its peers.
Frequency Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Frequency Therapeutics is estimated to be -2.26345 with future projections ranging from a low of -2.425 to a high of -1.965. Frequency Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -9.42. Please be aware that the consensus of earnings estimates for Frequency Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Frequency Therapeutics Earnings Estimation Breakdown
The calculation of Frequency Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Frequency Therapeutics is estimated to be -2.26345 with the future projection ranging from a low of -2.425 to a high of -1.965. Please be aware that this consensus of annual earnings estimates for Frequency Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.42 Lowest | Expected EPS | -1.97 Highest |
Frequency Therapeutics Earnings Projection Consensus
Suppose the current estimates of Frequency Therapeutics' value are higher than the current market price of the Frequency Therapeutics stock. In this case, investors may conclude that Frequency Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Frequency Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 9 | 76.48% | -1.92 | -2.26345 | -9.42 |
Frequency Therapeutics Ownership Allocation
The majority of Frequency Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Frequency Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Frequency Therapeutics. Please pay attention to any change in the institutional holdings of Frequency Therapeutics as this could imply that something significant has changed or is about to change at the company.Frequency Therapeutics Profitability Analysis
The company reported the previous year's revenue of 2.27 M. Net Loss for the year was (83.58 M) with profit before overhead, payroll, taxes, and interest of 46 K.About Frequency Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Frequency Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Frequency Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Frequency Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Frequency Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Frequency Therapeutics. We calculate exposure to Frequency Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Frequency Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2 M | 1.9 M | |
| Pretax Profit Margin | (42.25) | (40.14) | |
| Operating Profit Margin | (46.54) | (44.21) | |
| Net Loss | (42.32) | (40.21) | |
| Gross Profit Margin | 0.65 | 0.56 |
Frequency Therapeutics Current Valuation Indicators
Frequency Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Frequency Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Frequency Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Frequency Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Frequency Therapeutics' worth.When determining whether Frequency Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Frequency Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Frequency Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Frequency Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Frequency Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Frequency Stock, please use our How to Invest in Frequency Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Will Biotechnology sector continue expanding? Could Frequency diversify its offerings? Factors like these will boost the valuation of Frequency Therapeutics. Expected growth trajectory for Frequency significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Frequency Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Frequency Therapeutics requires distinguishing between market price and book value, where the latter reflects Frequency's accounting equity. The concept of intrinsic value - what Frequency Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Frequency Therapeutics' price substantially above or below its fundamental value.
Understanding that Frequency Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Frequency Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Frequency Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.